

April 6, 2020 09:00 PM GMT

NagaCorp | Asia Pacific

Cutting estimates due to Covid-19; Reiterate OW

Stock Rating
Overweight

Industry View
Attractive

Price Target
HK\$10.00

NagaCorp continues to grow more rapidly than its regional peers, and looks better positioned during the current downturn. Valuation of a 10% FCFE yield and 12x P/E on 2020e looks attractive on an absolute and relative basis, which should drive ongoing outperformance.

WHAT'S CHANGED

NagaCorp (3918.HK)	From	To
Price Target	HK\$15.00	HK\$10.00

Investment Conclusion - In the near term, we expect a significant decline in earnings estimates as NagaCorp reported strong 1Q20 revenue growth of 15% YOY, but was weaker than consensus/our expectation and closed the casino from 1 April 2020 indefinitely mainly due to Covid-19. The stock is currently trading at a 10% FCFE yield, 12x P/E and 5% Dividend yield on our lower than consensus estimates for 2021e and looks attractive in our view considering the monopoly status till 2045. We maintain our OW rating.

Higher exposure to China, ASEAN and VIP should help the company recover faster than regional peers. In 2019, Naga generated 71% of its Gross Gaming Revenue (GGR) and 41% of its gross profit from the VIP segment. We believe it will benefit since VIP should recover faster than Mass in our view. This is because the VIP segment, which has much higher revenue per customer, relies less on visitation recovery.

Solid Balance Sheet but still needs scrutiny - Despite gross cash of US\$327m by December 2019 which went up to US\$473m by March 2020, the company will have to ensure payments of: (A) US\$210m of 2019 final dividends in June 2020 and a future 60% dividend payout ratio, (B) repaying/refinancing a US\$300m 9.375% bond due mid 2021, and (C) Naga3 capex (US\$300m p.a.), maintaining cage capital (US\$50m) and annual fixed costs (US\$180m). In our model, we have assumed refinancing of the US\$300m bond at 7%, even though the yield has spiked up to 9.9% in April after bottoming at around 4% in January 2020.

What's changed? We have reduced our PT from HK\$15 to HK\$10, mostly because of reduced earnings mainly due to weaker demand from Covid-19 as well as closure of the casino from April 1, 2020. We also use 2021 FCF (earlier 2020) to calculate our PT, although the 8% target FCFE yield is unchanged. We have moved 5% potential revenue tax to 2021 (earlier 2020).

MORGAN STANLEY ASIA LIMITED+

Praveen K Choudhary

EQUITY ANALYST

Praveen.Choudhary@morganstanley.com

+852 2848-5068

Gareth Leung

RESEARCH ASSOCIATE

Gareth.Leung@morganstanley.com

+852 2848-7339

Single Stock Insights

Click Here for Collection >

NagaCorp (3918.HK, 3918 HK)

ASEAN Gaming / Hong Kong

Stock Rating	Overweight
Industry View	Attractive
Price target	HK\$10.00
Shr price, close (Apr 6, 2020)	HK\$8.15
52-Week Range	HK\$14.74-7.08
Up/downside to price target (%)	23
Sh out, dil, curr (mn)	4,341
Mkt cap, curr (mn)	US\$4,564
Avg daily trading value (mn)	HK\$62

Fiscal Year Ending	12/19	12/20e	12/21e	12/22e
ModelWare EPS (US\$)	0.120	0.065	0.091	0.103
Prior ModelWare EPS (US\$)	-	0.14	0.15	0.17
EPS (US\$)§	0.12	0.13	0.15	0.16
Revenue, net (US\$ mn)	1,755	1,207	1,471	1,613
EBITDA (US\$ mn)	661	451	539	592
ModelWare net inc (US\$ mn)	521	283	393	445
P/E	14.5	16.1	11.6	10.3
P/BV	4.2	2.6	2.3	2.1
RNOA (%)	31.4	15.3	16.4	16.6
ROE (%)	33.9	15.8	22.0	22.5
EV/EBITDA	11.6	11.0	9.2	8.3
Div yld (%)	4.9	3.7	5.2	5.9

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework

§ = Consensus data is provided by Thomson Reuters Estimates

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Investment Summary

Despite NagaCorp reporting strong 1Q20 revenue growth of 15%YOY, we lower our forecasts for 2020/21 EBITDA by 30-40% to reflect the Covid-19 impact (include casino closure from 1 April 2020 till further notice). Our 2021 EBITDA estimates are 18% lower than 2019; this is directionally similar to Macau (where 2021 is 14% lower than 2019; Please refer to page 9 of [our recent Macau industry note](#)), as we expect base mass business to have continued structural supply constraints due to social distancing. This drives our PT down to HK\$10.0 from HK\$15.0. However, we reiterate our OW rating for 3 key positives.

Key Positives:

(1) High exposure to VIP: In 2019, Naga generated 71% of its GGR and 41% of its gross profit from the VIP segment. We believe it will benefit since VIP should recover faster than Mass in our view. This is because the VIP segment, which has much higher revenue per customer, relies less on a visitation recovery.

(2) Attractive valuation considering monopoly status till 2045 - At a 10% FCFE yield, 12x P/E and 5% Dividend yield on 2021e, the stock is trading at a 10-16% discount to Macau peers. We expect the stock to continue to re-rate given its growth prospects and monopoly position. The 72% dividend payout ratio was a positive surprise to the market. We believe Naga will sustain a 60% payout ratio going forward.

(3) Balance sheet needs scrutiny but positive prospects in general: As of 1Q20, Naga had gross cash of US\$473mn (US\$327m by December 2019). Yet, the commitments are as follows: (A) paying US\$210m of a 2019 final dividend to be paid in June 2020 and a future 60% dividend payout ratio, (B) repaying or refinancing a US\$300m 9.375% bond due mid 2021, and (C) paying for Phase 3 capex (US\$300m per annum), maintaining cage capital (US\$50m) and annual fixed costs (US\$180m).


To fund these, we have estimated the company to refinance the bond at 7% before maturity. Even though the yield has recently spiked up to 9.9% in April 2020 (after bottoming at 4.4% in January 2020), we expect it to stabilize at a lower yield.

Key Concerns:

(1) Prolonged Covid-19 disruption: Cambodia closed all casinos from 1 April till further notice in an effort to contain the outbreak. We estimate the daily cash burn rate at roughly US\$0.5mn. We note that China, Malaysia and Singapore, countries where most of Naga's customers come from, continue to have travel restrictions in place, e.g. Guangdong province requires a 14-day quarantine for all entering persons, Malaysia banned overseas travel and Singapore requires quarantine for returning residents.

(2) New revenue tax timing remains an overhang: We think this is likely to be delayed as more pending bills are in the Cambodia Parliament due to the Covid-19 situation. In our bear case, the 5% tax starts in mid-2020 and could have an 11% negative impact on FCFE. However, our base case assumes the tax starts in 2021.

Exhibit 1: NagaCorp bond yield spiked up to 9.9% in April 2020 (after bottoming at 4.4% in January 2020); we expect it to stabilize at a lower yield



Source: Bloomberg as of 3 April 2020, Morgan Stanley Research

Operational Forecasts Summary Tables

Exhibit 2: Revenue and productivity forecast

Revenue US\$ mn	2018	2019	2020E	2021E	2022E
VIP revenue	1,069	1,243	828	991	1,090
Mass revenue	236	318	233	291	320
EGM revenue	129	158	118	160	173
GGR	1,434	1,719	1,179	1,442	1,583
Revenue growth YOY	2018	2019	2020E	2021E	2022E
VIP revenue	71%	16%	-33%	20%	10%
Mass revenue	57%	35%	-27%	25%	10%
EGM revenue	-14%	22%	-25%	36%	8%
GGR	55%	20%	-31%	22%	10%
Tables (period end)	2018	2019	2020E	2021E	2022E
VIP tables	325	349	349	349	349
Mass tables	154	174	174	174	174
EGM machines	1,950	2,000	2,200	2,200	2,200
Productivity (US\$)	2018	2019	2020E	2021E	2022E
VIP w/t/d	10,227	10,106	6,480	7,776	8,553
Mass w/t/d	4,454	5,238	3,666	4,583	5,041
EGM w/u/d	259	337	236	307	331

Source: Company data, Morgan Stanley Research (E) estimates

Exhibit 3: Operational summary

Operation (US\$ mn)	2018	2019	2020E	2021E	2022E
Gross Revenue	1,474	1,755	1,207	1,471	1,613
VIP Revenue	1,069	1,243	828	991	1,090
Mass Revenue	236	318	233	291	320
EGM Revenue	129	158	118	160	173
Gross Gaming Revenue (GGR)	1,434	1,719	1,179	1,442	1,583
Non-Gaming Revenue	40	36	28	29	30
Gross Profit					
Total	674	846	613	760	832
VIP	286	347	243	291	320
Mass	229	316	232	289	317
EGM	126	155	115	157	169
Gaming	641	817	590	736	806
Non-Gaming	32	30	23	24	25
Gross Margin					
Total	46%	48%	51%	52%	52%
VIP	27%	28%	29%	29%	29%
Mass	97%	99%	99%	99%	99%
EGM	98%	98%	98%	98%	98%
Gaming	45%	47%	50%	51%	51%
Non-Gaming	81%	83%	83%	83%	83%
Net Profit					
Opex	(973)	(1,095)	(756)	(932)	(1,021)
EBITDA (calculated)	502	661	451	539	592
- YOY	61%	32%	-32%	20%	10%
PAT	391	521	283	393	445

Source: Company data, Morgan Stanley Research (E) estimates

What's Changed

We cut our PT from HK\$15.0 to HK\$10.0. This is driven by our 31% cut in 2021 Corporate EBITDA as we now peg valuation to 2021 FCFE with an 8% yield (unchanged), which should be the first "normal" year after Covid-19.

For 2020, we lower our revenue by 33% to reflect the Cambodia casinos closure started on 1 April and the impact of Covid-19. Due to negative operating leverage, this drives our EBITDA and EPS to decrease at a larger degree by 41% and 53% respectively. The cut in EPS is also due to 22% higher interest expenses as we now expect Naga to raise an extra US\$100mn debt in 2020 to maintain the dividend (with the payout ratio at 60%) and capex on maintenance and Naga3 amidst a business downturn from Covid-19.

For 2021, we lower our revenue by 26% as we expect 2021 not to come back to the 2019 level due to continued social distancing and the potential negative wealth effect and because Cambodia is likely to recover more slowly than Macau. This drives our EBITDA and EPS to decrease by 31% and 41% respectively. The cut in EPS is also due to higher interest expenses (from US\$13mn previously to US\$31mn). This is because we expect Naga to refinance its US\$300mn 9.375% senior notes at a lower rate of 7% when it matures by May 2021.

Comparison with Consensus

We are 35-40% lower in 2020/21 Revenue and EBITDA forecasts. We are also 50% and 39% lower in terms of 2020 and 2021 EPS respectively. The consensus has not taken into account the impact from Covid-19 yet (2020 and 2021 EBITDA revisions are -3% YTD only). There should be further negative revisions for both 2020 and 2021, in our view.

Exhibit 4: Morgan Stanley Research estimates: New vs. Old

US\$ mn	New		Old		Variance	
	2020E	2021E	2020E	2021E	2020E	2021E
Revenue	1,207	1,471	1,801	1,984	-33%	-26%
Corporate EBITDA	451	539	760	777	-41%	-31%
Net Income	283	393	607	662	-53%	-41%
EPS (US cents)	6.53	9.06	13.97	15.24	-53%	-41%

Source: Morgan Stanley Research (E) estimates

Exhibit 5: Morgan Stanley Research estimates vs. consensus

US\$ mn	MSe		Consensus		Variance	
	2020E	2021E	2020E	2021E	2020E	2021E
Revenue	1,207	1,471	1,962	2,235	-39%	-34%
Corporate EBITDA	451	539	737	839	-39%	-36%
Net Income	283	393	565	649	-50%	-39%
EPS (US cents)	6.53	9.06	13.09	14.86	-50%	-39%

Source: Refinitiv as of 2 Apr 2020, Morgan Stanley Research

Valuation

Our PT is from an 8% FCFE yield (unchanged) on 2021 FCFE, which should be the first full "normal" year after Covid-19, in our view.

We think the current valuation is reasonable at a 10% FCFE yield and 5% Dividend yield on 2021e, implying a 10% and 16% discount to Macau peers. Naga is also more than 1SD cheaper than the long-term average (since 2012) in terms of forward FCFE yield, forward EV/EBITDA and forward P/E. However, we see further negative revisions as 2020 EBITDA revisions are -3% YTD.


NagaCorp has paid out over 60% of its earnings every year since 2015 (72% in 2019). We expect this to continue and to drive above-peer dividend yields of 5-6% in 2021-22e.

Exhibit 6: Naga: FCFE valuation and multiples

US\$ m	2019	2020E	2021E	2022E
Company EBITDA	661	451	539	592
Less: Income tax	(30)	(30)	(8)	(8)
Less: Maintenance Capex	(50)	(50)	(50)	(50)
Less: Interest Expense, Net	(16)	(34)	(31)	(28)
FCFE	565	336	450	506
Target FCFE Yield			8.0%	
Equity Value		4,205	5,630	6,330
Number of shares			4,341	
Price Target (HK\$)			10.0	
Upside/downside			22%	
Current multiples	2019	2020E	2021E	2022E
EV/EBITDA	6.8	9.9	8.4	8.2
P/E	8.7	16.1	11.6	10.2
Recurring FCFE Yield	12.4%	7.4%	9.9%	11.1%
Div Yield%	8.0%	3.7%	5.1%	5.8%

Source: Refinitiv as of 2 Apr, 2020, Company data, Morgan Stanley Research (E) estimates

Exhibit 7: NagaCorp forward FCFE yield (%) based on consensus EBITDA




Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research

Exhibit 8: Asia Gaming Valuation Comps

2-Apr-20	Current Price	MS Rating	Mkt Cap (US\$ m)	6M Avg Vol. (US\$ m)	EV/EBITDA			P/E			FCFE Yield			Div Yield			Net Debt/EBITDA			2019 Perf.	2020 YTD Perf.
	LOC\$				2019	2020E	2021E	2019	2020E	2021E	2019	2020E	2021E	2019	2020E	2021E	2019	2020E	2021E		
MACAU																					
Sands China	27.8	EW	29,008	67	10.5x	21.1x	12.0x	13.9x	57.0x	18.3x	8.7%	3.3%	7.1%	7.2%	7.2%	7.2%	1.0x	2.0x	1.1x	22%	-33%
Galaxy	41.3	EW	23,096	96	8.5x	16.9x	9.6x	13.0x	47.2x	18.8x	9.5%	4.9%	8.2%	2.2%	1.0%	1.9%	(2.3x)	(4.6x)	(2.6x)	15%	-28%
Wynn Macau	11.5	OW	7,737	24	9.1x	19.7x	11.8x	12.7x	-127.8x	24.6x	11.7%	3.3%	8.2%	5.6%	0.0%	5.2%	2.7x	5.7x	3.4x	12%	-40%
Melco Resorts (Attri.)	11.6	OW	5,632	50	8.6x	27.3x	10.6x	NA	NA	28.0x	13.2%	-0.5%	9.3%	5.6%	5.7%	5.7%	2.9x	9.1x	3.5x	35%	-52%
MGM China	7.7	OW	3,780	13	7.6x	20.4x	9.4x	13.8x	-18.4x	27.0x	13.9%	2.1%	11.3%	2.3%	0.0%	2.4%	2.4x	6.5x	3.0x	22%	-39%
SJM	6.3	OW	4,628	14	6.3x	30.0x	7.5x	10.5x	237.9x	18.1x	9.8%	1.1%	10.2%	4.7%	0.3%	3.3%	0.2x	(0.6x)	(0.1x)	-3%	-29%
Macau average (ex Studio)			73,881		8.4x	22.5x	10.2x	12.8x	39.2x	22.5x	11.1%	2.4%	9.1%	4.6%	2.3%	4.3%	1.1x	3.0x	1.4x	17%	-37%
ASEAN																					
Bloomberry	6.0	OW	1,292	1	4.7x	5.2x	4.8x	6.4x	7.8x	6.4x	18.1%	15.3%	18.0%	6.7%	3.9%	4.7%	1.4x	1.6x	1.5x	20%	-47%
NagaCorp	8.2	OW	4,581	9	6.8x	9.9x	8.4x	8.7x	16.1x	11.6x	12.4%	7.4%	9.9%	8.0%	3.7%	5.1%	(0.0x)	(0.0x)	(0.0x)	62%	-40%
Genting Singapore	0.7	EW	5,601	17	3.3x	4.0x	3.8x	11.6x	15.0x	14.1x	12.0%	10.5%	10.9%	6.0%	6.0%	6.0%	(3.2x)	(3.7x)	(3.5x)	-6%	-28%
ASEAN average			11,473		4.9x	6.4x	5.7x	8.9x	13.0x	10.7x	14.1%	11.1%	12.9%	6.9%	4.5%	5.3%	(0.6x)	(0.7x)	(0.7x)	25%	-38%


Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research (E) estimates

Exhibit 9: NagaCorp forward EV/EBITDA on consensus estimates




Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research

Exhibit 10: NagaCorp forward P/E on consensus estimates




Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research

Exhibit 11: Naga's 2020E consensus EBITDA revisions since Jan 2019



Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research

Exhibit 12: Naga's 2021E consensus EBITDA revisions since Jan 2019



Source: Refinitiv as of 2 Apr, 2020, Morgan Stanley Research estimates


Risk Reward – NagaCorp (3918.HK)

Upside driven by capacity expansion in Cambodia

PRICE TARGET HK\$10.00

Our price target of HK\$10.0 is our base case scenario value. We apply a target FCFE yield of 8.0% to our 2021 estimate, higher than Macau peers' average of 7.0%. Our 8.0% target FCFE yield is lower than the company's long-term average of 11% since 2012 in view of the company's leading position in a growing market, stable dividend, tax profile, and Naga 2 ramp-up.


Consensus Price Target Distribution



Source: Thomson Reuters, Morgan Stanley Research

◆ Mean ◆ Morgan Stanley Estimates

RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Thomson Reuters, Morgan Stanley Research

OVERWEIGHT THESIS

- Capacity expansion at Naga 2 has been successful and is still ramping up.
- China's Belt and Road Initiative (BRI) and growth in Chinese visitor numbers should continue to drive VIP and mass earnings growth though, in the near term, growth may slow down due to travel restrictions.
- Naga has better license terms, lower taxes and lower labor costs compared to Macau gaming companies.
- Naga offers higher dividends and growth compared to ASEAN gaming peers.
- Reasonable valuation at 8x EV/EBITDA, 12x P/E, FCFE yield of 10% and dividend yield of 5% on 2021e.

Consensus Rating Distribution



● MS Rating

Source: Thomson Reuters, Morgan Stanley Research

Risk Reward Themes

- Pricing Power: *Positive*
 Regulation: *Negative*
 Secular Growth: *Positive*

View descriptions of Risk Rewards Themes, [here](#)

BULL CASE

HK\$13.00

6.0% recurring FCFE yield 2021e

Same GGR and EBITDA estimates as base case. Lower FCFE yield at 6.0%.

BASE CASE

HK\$10.00

8.0% recurring FCFE yield 2021e

Continued Naga 2 ramp in 2020-21. VIP revenue growth of -33%/+20% in 2020/21; Mass (table + slot) revenue growth of -27%/+25% in 2020/21.

BEAR CASE

HK\$4.00

12.0% recurring FCFE yield 2021e

Downturn in overall economy. Slower-than-expected recovery from Covid-19. More competition from Vietnam. Reduced visitation. Slower-than-expected Naga 2 ramp. VIP revenue growth of -43%/0% in 2020/21; Mass (incl Slot) revenue growth of -37%/0% in 2020/21.

Risk Reward – NagaCorp (3918.HK)


KEY EARNINGS INPUTS

Drivers	2019	2020e	2021e	2022e
Company VIP Revenue Growth (%)	16	(33)	20	10
Company Mass & Slot Revenue Growth (%)	30	(26)	30	9
Corporate EBITDA margin (Gross) (%)	38	37	37	37

INVESTMENT DRIVERS

- Reopening of Cambodia casinos, lifting of travel restrictions in China, Malaysia and Singapore.
- New junkets opening in 2020.
- Removal of overhang with respect to tax rate in Cambodia in 2020/21.

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies, [here](#)

RISKS TO PT/RATING

RISKS TO UPSIDE

- Faster-than-expected recovery from Covid-19.
- Recent workers' strike in Jan results in lower-than-expected labor costs rises.

RISKS TO DOWNSIDE

- Potential share dilution for future developments and expansion.
- Regional competition (e.g., Vietnam, Philippines, Korea, Macau, Singapore, Sihanoukville etc.).
- Slower-than-expected recovery from Covid-19.
- High exposure to VIP revenue and risk to overall global VIP business.

OWNERSHIP POSITIONING

Inst. Owners, % Active 79.3%

Source: Thomson Reuters, Morgan Stanley Research

MS ESTIMATES VS. CONSENSUS

FY Dec 2020e



◆ Mean ◆ Morgan Stanley Estimates

Source: Thomson Reuters, Morgan Stanley Research

Financial Summary

Exhibit 13: NagaCorp Financial Summary

Nagacorp Ltd.

For the years ending December 31									
Income Statement					Balance Sheet				
US\$ million	2019A	2020E	2021E	2022E	US\$ million	2019A	2020E	2021E	2022E
Gross Revenue	1,755	1,207	1,471	1,613	Fixed Assets	1,595	1,868	2,087	2,226
VIP Revenue	1,243	828	991	1,090	Intangible Assets	156	153	149	146
Mass Revenue	318	233	291	320	Others	140	140	140	140
EGM Revenue	158	118	160	173	Non-Current Assets	1,891	2,160	2,375	2,512
Non-Gaming Revenue	36	28	29	30	Debtors	127	109	132	145
Gaming tax (5% of GGR)		-	(72)	(79)	Cash and deposits	327	114	94	153
Cost of sales	(909)	(594)	(711)	(782)	Current Assets	456	226	228	301
Gross profit	846	613	760	832	Creditors	159	104	125	137
VIP	347	243	291	320	Others	16	16	16	16
Mass	316	232	289	317	Current Liabilities	175	120	140	153
EGM	155	115	157	169	Senior notes	295	395	395	395
Non-Gaming	30	23	24	25	Lease liabilities	49	49	49	49
Administrative expenses	(61)	(57)	(63)	(68)	Others	40	40	40	40
Other operating expenses	(84)	(78)	(86)	(93)	Non-Current Liabilities	384	484	484	484
EBITDA	661	451	539	592	Share Capital	54	54	54	54
Depreciation	(96)	(106)	(110)	(114)	Reserves	1,734	1,729	1,925	2,122
Amortization of license	(3)	(3)	(3)	(3)	Shareholders' Equity	1,788	1,783	1,980	2,176
EBIT	561	341	425	474					
Profit before tax	552	314	401	453	Ratios	2019A	2020E	2021E	2022E
Income Tax	(30)	(30)	(8)	(8)	Gross Profit Margin (%)	48%	51%	52%	52%
Profit after tax	521	283	393	445	- VIP	28%	29%	29%	29%
Basic EPS (US\$ cents)	12.01	6.53	9.06	10.25	- Mass	99%	99%	99%	99%
DPS (US\$ cents)	8.48	3.92	5.43	6.15	- EGM	98%	98%	98%	98%
					- Non-gaming	83%	83%	83%	83%
					EBITDA Margin (%)	38%	37%	37%	37%
					Dividend Payout Ratio (total)	71%	60%	60%	60%
					GGR Growth	20%	-31%	22%	10%
					VIP Growth	16%	-33%	20%	10%
					Mass Growth	35%	-27%	25%	10%
					EGM Growth	22%	-25%	36%	8%
					EBITDA Growth	32%	-32%	20%	10%
					Net Profit Growth	33%	-46%	39%	13%
					Operating Data				
					VIP Tables (avg)	337	349	349	349
					Mass Tables (avg)	167	174	174	174
					EGM Machines (avg)	1,975	2,100	2,200	2,200
					VIP win/table/Day (US\$)	10,106	6,480	7,776	8,553
					Mass win/table/Day (US\$)	5,238	3,666	4,583	5,041
					EGM win/unit/Day (US\$)	337	236	307	331
					Visitors to Cambodia (m)	8.5	8.9	9.4	9.8

Source: Company data, Morgan Stanley Research (E) estimates

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (BSE Registration No. INB011054237 and NSE Registration No. INB/INF231054231), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-372-2014) which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and/or PT. Morgan Stanley Sekuritas Indonesia and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Praveen K Choudhary.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict/policies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Melco Resorts & Entertainment Ltd. Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Melco Resorts & Entertainment Ltd, **NagaCorp**. In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Bloomberry Resorts Corporation, Galaxy Entertainment, Genting Singapore PLC, Las Vegas Sands Corp., Melco Resorts & Entertainment Ltd, MGM China Holdings Limited, **NagaCorp**, SJM Holdings, Wynn Macau, Limited.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Genting Singapore PLC, Las Vegas Sands Corp., Melco Resorts & Entertainment Ltd, **NagaCorp**, Wynn Macau, Limited.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Bloomberry Resorts Corporation, Galaxy Entertainment, Genting Singapore PLC, Las Vegas Sands Corp., Melco Resorts & Entertainment Ltd, MGM China Holdings Limited, **NagaCorp**, SJM Holdings, Wynn Macau, Limited.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Genting Singapore PLC, Las Vegas Sands Corp., Melco Resorts & Entertainment Ltd, **NagaCorp**, Wynn Macau, Limited.

Morgan Stanley & Co. LLC makes a market in the securities of Las Vegas Sands Corp., Melco Resorts & Entertainment Ltd.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of March 31, 2020)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

STOCK RATING CATEGORY	COVERAGE UNIVERSE		INVESTMENT BANKING CLIENTS (IBC)			OTHER MATERIAL INVESTMENT SERVICES CLIENTS (MISC)	
	COUNT	% OF TOTAL	COUNT	% OF TOTAL IBC	% OF RATING CATEGORY	COUNT	% OF TOTAL OTHER MSC
Overweight/Buy	1228	38%	306	44%	25%	543	37%
Equal-weight/Hold	1437	45%	322	46%	22%	702	48%
Not-Rated/Hold	2	0%	0	0%	0%	2	0%
Underweight/Sell	543	17%	72	10%	13%	212	15%
TOTAL	3,210		700			1459	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to www.morganstanley.com/researchdisclosures.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of Las Vegas Sands Corp., Sands China Ltd., Wynn Macau, Limited.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions. Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>).

In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies

please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley Research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Indonesia by PT. Morgan Stanley Sekuritas Indonesia; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

Morgan Stanley Hong Kong Securities Limited is the liquidity provider/market maker for securities of Galaxy Entertainment, Las Vegas Sands Corp., Sands China Ltd. listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: <http://www.hkex.com.hk>.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to

which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client. The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

INDUSTRY COVERAGE: ASEAN Gaming

COMPANY (TICKER)	RATING (AS OF)	PRICE* (04/06/2020)
Praveen K Choudhary		
Bloomberry Resorts Corporation (BLOOMP.S)	O (03/26/2018)	PP\$5.89
Genting Singapore PLC (GENS.SI)	E (04/04/2019)	S\$0.69
NagaCorp (3918.HK)	O (09/23/2019)	HK\$8.15

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.